Comparison of serum 25-hydroxy vitamin D amongst black African prostate cancer patients with non-aggressive versus aggressive disease using the Gleason score


  • Julius O. Akhaine Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
  • Venyir M. Ramyil Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
  • Nuhu K. Dakum Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
  • Christian O. Isichei Department of Chemical Pathology, Jos University Teaching Hospital, Jos, Nigeria
  • Samaila I. Shuaibu Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
  • Chimaobi G. Ofoha Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria



Serum 25-hydroxy vitamin D, Prostate cancer, Gleason score


Background: Black men of African descent have higher risk for developing prostate cancer and present at a younger age with advanced disease and a poorer prognosis. Limited number of studies directly linking serum vitamin D with either prostate cancer prognosis or measures of prostate cancer aggressiveness have been done. The objective of this study is to compare serum 25 hydroxy vitamin D levels in patients with non-aggressive and aggressive prostate cancer using the Gleason score in black Africans in Jos.

Methods: A cross sectional study conducted among fifty patients who presented to the urological surgical out-patient clinic of the Jos University Teaching Hospital who had clinical diagnosis of prostate cancer and were scheduled for prostate biopsy. Blood samples for serum 25-hydroxy vitamin D assay was analysed using the enzyme linked immunosorbent assay (ELISA) technique, patients with histologically confirmed prostate cancer were analysed. Data was collected in a proforma, statistical analysis done using statistical package for the social sciences (SPSS)(R) version 23 and t-test was used for comparison with a p value <0.05 considered significant.

Results: Fifty patients were studied whose age ranged from 50-89 years. The mean level of serum 25-hydroxy vitamin D was 37.90 ng/ml±17.92. The mean serum 25-hydroxy vitamin D of patients with non-aggressive disease (GS≤6) and aggressive disease (GS≥7) was 48.44±17.09 and 34.57±17.08 respectively with a p value of 0.018.

Conclusions: This study showed that black African prostate cancer patients with high grade tumors (Gleason score ≥7) had significantly lower 25-hydroxy vitamin D levels compared to those with low grade tumors (Gleason score <7).


Adeloye D, David RA, Aderemi AV, Iseolorunkanmi A, Oyedokun A, Iweala EE, et al. An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(4):e0153496.

Stephenson AJ, Klein EA. Epidemiology, Etiology, and Prevention of Prostate cancer. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier. 2016;2543-64.

Nelson SM, Batai K, Ahaghotu C, Agurs-Collins T, Kittles RA. Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men. Nutrients. 2016;9(1):12.

Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131:1187-96.

Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes and Control. 2010;21.

Osegbe DN. Prostate cancer in Nigerians: Facts and nonfacts. J Urolo. 1997;157:13403.

Badmus TA, Adesunkanmi ARK, Yusuf BM, Oseni GO, Eziyi AK, Bakare TIB, et al. Burden of prostate cancer in southwestern nigeria. Urology. 2010;76(2):412-6.

Nwofor AME, Oranusi CK. cancer of the prostate, Nnewi experience. Medical and Dental Consultants’ Association of Nigeria (MDCAN). 2004;65-8.

Ibrahim AG, Aliyu S, Dogo HM, Babayo UD, Zarami AB. Carcinoma of the Prostate - A Five Year Experience in Maiduguri North Eastern Nigeria. Int J Appl Res. 2015;1(8):512-4.

Wang WL, Tenniswood M. Vitamin D, intermediary metabolism and prostate cancer tumor progression. Front Physiol. 2014;5:183.

Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Therap Med. 2011;2:181-93.

Yaturu S, Zdunek S, Youngberg B. Vitamin D Levels in Subjects with Prostate Cancer Compared to Age-Matched Controls. Prostate Cancer. 2012;1-4.

Nnabugwu II, Udeh EI, Ugwumba FO, Ozoemena FO. Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. Clin Intervent Aging. 2016;11:961-6.

Galunska B, Gerova D, Kosev P, Anakievski D. Serum 25-hydroxy vitamin D levels in Bulgarian patients with prostate cancer_ a pilot study. Clin lab. 2015;61(3):329-35.

Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CMP, Nadler RB, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014;20(9):2289-99.

Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104:690-9.






Original Research Articles